tbuckley/cabot-search huggingface dataset:
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
Authors: James C.H. Yang, Sang-We Kim, Dong-Wan Kim, Jong-Seok Lee, Byoung Chul Cho, Jin-Seok Ahn, Dae H. Lee, Tae Min Kim, Jonathan W. Goldman, Ronald B. Natale, Andrew P. Brown, Barbara Collins, Juliann Chmielecki, Karthick Vishwanathan, Ariadna Mendoza-Naranjo, Myung-Ju Ahn
Journal: Journal of Clinical Oncology (2019)

In this phase I study (BLOOM), osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was evaluated in patients with leptomeningeal metastases (LMs) from EGFR-mutated (EGFRm) advanced non-small-cell lung cancer (NSCLC) whose disease had progressed on previous EGFR-TKI therapy.Patients with cytologically confirmed LM received osimertinib 160 mg once daily. Objectives were to assess confirmed objective response rate (ORR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), pharmacokinetics (PK), and safety. Additional efficacy evaluations included changes from baseline in CSF cytology and neurologic examination. Measurable lesions were assessed by investigator according to RECIST version 1.1. LMs were assessed by neuroradiologic blinded central independent review (BICR) according to Response Assessment in Neuro-Oncology LM radiologic criteria and by investigator.Forty-one patients were enrolled. LM ORR and DoR by neuroradiologic BICR were 62% (95% CI, 45% to 78%) and 15.2 months (95% CI, 7.5 to 17.5 months), respectively. Overall, ORR by investigator was 41% (95% CI, 26% to 58%), and median DoR was 8.3 months (95% CI, 5.6 to 16.5 months). Median investigator-assessed PFS was 8.6 months (95% CI, 5.4 to 13.7 months) with 78% maturity; median OS was 11.0 months (95% CI, 8.0 to 18.0 months) with 68% maturity. CSF tumor cell clearance was confirmed in 11 (28%; 95% CI, 15% to 44%) of 40 patients. Neurologic function was improved in 12 (57%) of 21 patients with an abnormal assessment at baseline. The adverse event and PK profiles were consistent with previous reports for osimertinib.Osimertinib showed meaningful therapeutic efficacy in the CNS and a manageable safety profile at 160 mg once daily in patients with EGFRm NSCLC and LM.
EFFECTS OF GRADED CORONARY CONSTRICTION ON REGIONAL OXYGEN AND CARBON DIOXIDE TENSIONS IN OUTER AND INNER LAYERS OF THE CANINE MYOCARDIUM
Authors: Mitsuhiro Yokoyama, Kishio Maekawa, Yutaka Katada, Yuichi Ishikawa, Takayoshi Azumi, Tetsuo Mizutani, Hisashi Fukuzaki, Tatsuya Tomomatsu
Journal: Circulation (1978)

This study was undertaken to investigate the effects of graded coronary constriction on regional gas tensions of the myocardium. In 12 open chest dogs, tissue carbon dioxide (PtCO2) and oxygen (PtO2) tensions were measured simultaneously in outer and inner layers of the myocardium using a mass spectrometer. In normal condition, higher PtO2 and lower PtCO2 were observed in outer layer than in inner layer. With application of coronary constriction, increase in PtCO2 and decrease in PtO2 were observed in both layers of the myocardium, but the response to the ischemic stimuli by applying coronary constriction in inner layer was different from that in outer layer. Severe coronary constriction, more than 90% in its diameter, was necessary to produce significant changes in both gas tensions in both layers of the myocardium. Decrease in PtO2 was found in the condition of less severe coronary constriction and to be greater in inner layer than in outer layer of the myocardium. In terms of the changes in PtCO2, inner layer was also more susceptible to the ischemic stimuli than outer layer. The greater and earlier elevation of PtCO2 in inner layer than in outer layer is regarded as one of the possible mechanisms of the reduction of myocardial contraction in the early stage of myocardial ischemia.
Genetic Activation of NRF2 By KEAP1 Inhibition Induces Fetal Hemoglobin Expression and Triggers Anti-Oxidant Stress Response in Erythroid Cells
Authors: Dipti Gupta, Samuel Lessard, Nancy Moore, Jicheng Duan, Yukio Nakamura, Feng-Chun Yang, Alexandra Hicks, David R. Light, Sriram Krishnamoorthy
Journal: Blood (2019)
A Phase II Trial of Combination Bortezomib (Velcade®) and Rituximab for Untreated “High Tumor Burden” Indolent Non-Hodgkin Lymphoma (NHL).
Authors: Kevin A. David, Mitchell R. Smith, Izidore S. Lossos, Eren Roubal, Jane N. Winter, Steve T. Rosen, Leo I. Gordon, Andrew M. Evens
Journal: Blood (2008)
A Phase I/II Trial of Bortezomib, Tacrolimus and Methotrexate for Prophylaxis of Acute Graft Versus Host Disease after HLA Mismatched Reduced Intensity Transplantation.
Authors: John Koreth, Kristen Stevenson, Haesook T Kim, Vincent T Ho, Corey S Cutler, Philippe Armand, Robert J Soiffer, Joseph H Antin, Edwin P Alyea
Journal: Blood (2008)
Responses and Outcome of Immunosuppressive Therapy in Thymoma-Associated Pure Red Cell Aplasia: A Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group.
Authors: Makoto Hirokawa, Ken-ichi Sawada, Naohito Fujishima, Shinji Nakao, Akio Urabe, Mitsuhiro Omine, Keiya Ozawa
Journal: Blood (2006)
A Randomised, Double-Blind, Placebo Controlled, Multicentre Trial of ATL-104, a Swallowable Mouthwash, in Patients with Oral Mucositis Following Peripheral Blood Stem Cell Transplantion (PBSCT).
Authors: Ann Hunter, Prem Mahendra, Keith Wilson, Paul Fields, Gordon Cook, Andrew Peniket, Charles Crawley, Rob Hallam, Roger Hickling, Richard Palmer, Robert Marcus
Journal: Blood (2006)
Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function
Authors: Hye Ryun Kim, Hyo Jin Park, Jimin Son, Jin Gu Lee, Kyung Young Chung, Nam Hoon Cho, Hyo Sup Shim, Seyeon Park, Gamin Kim, Hong In Yoon, Hyun Gyung Kim, Yong Woo Jung, Byoung Chul Cho, Seong Yong Park, Sun Young Rha, Sang-Jun Ha
Journal: Journal for ImmunoTherapy of Cancer (2019)

<h3>Background</h3> Regulatory T (T<sub>reg</sub>) cells have an immunosuppressive function in cancer, but the underlying mechanism of immunosuppression in the tumor microenvironment (TME) is unclear. <h3>Methods</h3> We compared the phenotypes of T cell subsets, including T<sub>reg</sub> cells, obtained from peripheral blood, malignant effusion, and tumors of 103 cancer patients. Our primary focus was on the expression of immune checkpoint (IC)-molecules, such as programmed death (PD)-1, T-cell immunoglobulin and mucin-domain containing (TIM)-3, T cell Ig and ITIM domain (TIGIT), and cytotoxic T lymphocyte antigen (CTLA)-4, on T<sub>reg</sub> cells in paired lymphocytes from blood, peritumoral tissue, and tumors of 12 patients with lung cancer. To identify the immunosuppressive mechanisms acting on tumor-infiltrating T<sub>reg</sub> cells, we conducted immunosuppressive functional assays in a mouse model. <h3>Results</h3> CD8<sup>+</sup>, CD4<sup>+</sup> T cells, and T<sub>reg</sub> cells exhibited a gradual upregulation of IC-molecules the closer they were to the tumor. Interestingly, PD-1 expression was more prominent in T<sub>reg</sub> cells than in conventional T (T<sub>conv</sub>) cells. In lung cancer patients<sub>,</sub> higher levels of IC-molecules were expressed on T<sub>reg</sub> cells than on T<sub>conv</sub> cells, and T<sub>reg</sub> cells were also more enriched in the tumor than in the peri-tumor and blood. In a mouse lung cancer model, IC-molecules were also preferentially upregulated on T<sub>reg</sub> cells, compared to T<sub>conv</sub> cells. PD-1 showed the greatest increase on most cell types, especially T<sub>reg</sub> cells, and this increase occurred gradually over time after the cells entered the TME. PD-1 high-expressing tumor-infiltrating T<sub>reg</sub> cells displayed potent suppressive activity, which could be partially inhibited with a blocking anti-PD-1 antibody. <h3>Conclusions</h3> We demonstrate that the TME confers a suppressive function on T<sub>reg</sub> cells by upregulating IC-molecule expression. Targeting IC-molecules, including PD-1, on T<sub>reg</sub> cells may be effective for cancer treatment.
Dyrk-3 Kinase Is an Erythroid Cell-Intrinsic Attenuator of Stress Erythropoiesis.
Authors: Olga Bogacheva, Oleg Bogachev, Madhu Menon, Elizabeth Valoret, Vinit Karur, H. Prosser, Caretha Creasy, Connie Erickson-Miller, Don Wojchowski
Journal: Blood (2005)
PTCy BMT for RDEB
Authors: C.L. Ebens, J.A. McGrath, K. Tamai, A. Hovnanian, J.E. Wagner, M.J. Riddle, D.R. Keene, T.E. DeFor, R. Tryon, M. Chen, D.T. Woodley, K. Hook, J. Tolar
Journal: British Journal of Dermatology (2019)

Generalised severe recessive dystrophic epidermolysis bullosa (RDEB‐GS) is a rare, incurable genetic disorder in which an essential skin component, type 7 collagen (C7), is defective or missing. As a result, skin and mucous membranes detach from the body, causing blisters and wounds. Bone marrow transplantation (BMT) can restore C7 in the skin, probably by supplying mesenchymal stem cells (MSCs) which turn into healthy new skin cells. However, BMT is a risky and unpleasant procedure because the drugs needed to stop the patient's immune system rejecting the donated bone marrow can themselves cause illness and sometimes death. Immune cells in the transplanted tissue may even attack the patient, causing graft versus host disease (GvHD). These doctors at the University of Minnesota tried a different BMT protocol in 10 children with RDEB‐GS, using less intense immune‐suppression pre‐transplant. Three days post‐transplant they gave an immunosuppressive drug called cyclophosphamide (PTCy). Two months later, when the patient's body had accepted the donor tissue, they were able to give more MSCs from the same donor. The graft failed in three patients, two of whom underwent repeat BMT followed in one by severe complications and death a year later. Successfully transplanted patients tended to show more C7 in their skin biopsies and improved symptoms with reductions in itch, pain and areas of blistered skin. None suffered GvHD in the short term. The authors conclude that PTCy BMT is feasible in people with RDEB‐GS, even with “less‐than‐perfectly‐matched” donors, and allows repeat “top‐up” MSC grafts from the same donor.
Patient-Centered Standards for Medically Integrated Dispensing: ASCO/NCODA Standards
Authors: Melissa S. Dillmon, Erin B. Kennedy, Mary K. Anderson, Michael Brodersen, Howard Cohen, Steven L. D′Amato, Patty Davis, Gury Doshi, Stuart Genschaw, Issam Makhoul, Wayne Ormsby, Rajiv Panikkar, Eileen Peng, Luis E. Raez, Ellen A. Ronnen, Bill Wimbiscus, Michael Reff
Journal: Journal of Clinical Oncology (2019)

PURPOSE To provide standards for medically integrated dispensing of oral anticancer drugs and supportive care medications. METHODS An Expert Panel was formed, and a systematic review of the literature on patient-centered best practices for the delivery of oral anticancer and supportive care drugs was performed to April 2019 using PubMed and Google Scholar. Available patient-centered standards, including one previously developed by the National Community Oncology Dispensing Association (NCODA), were considered for endorsement. Public comments were solicited and considered in preparation of the final manuscript. RESULTS A high-quality systematic review that was current to May 2016 was adopted into the evidence base. Five additional primary studies of multifaceted interventions met the inclusion criteria. These studies generally included a multicomponent intervention, often led by an oncology pharmacist, and also included patient education and regular follow-up and monitoring. These interventions resulted in significant improvements to patient quality and safety and demonstrated improvements in adherence and other patient outcomes. CONCLUSION The findings of the systematic review were consistent with the NCODA patient-centered standards for patient relationships and education, adherence, safety, collection of data, documentation, and other areas. NCODA standards were adopted and used as basis for these American Society of Clinical Oncology/NCODA standards. Additional information is available at www.asco.org/mid-standards .
Abstract 14267: Integrative Epidemiological and Functional Analyses Identify Protein C as a Novel, Causal Factor in Arterial and Venous Disease
Authors: Dirk S Paul, David Stacey, Lingyan Chen, Joanna M Howson, Amy M Mason, Stephen Burgess, John Danesh
Journal: Circulation (2019)

Population-scale genomic analyses have transformed our understanding of the contribution of genetic variation to the risk of cardiovascular disease. However, a major challenge in unlocking the pote...
Clinical and Epidemiological Features of Hepatitis among the Residents of the Transcarpathian Region
Authors: A.I. Kohutych, H.M. Koval, Ye.S. Sirchak
Journal: GASTROENTEROLOGY (2020)

The clinical and epidemiological features of hepatitis A in the Transcarpathian region for years 2004–2014 were indicated. A specific cyclicism and seasonality of hepatitis A in this region of Ukraine was established. Based on the examination of 61 patients with hepatitis A a peculiarity of the clinical progression of the disease, and, also, specific microbiological changes of the quantitative and qualitative composition of the colon microflora, depending on the presence of a concomitant chronic pathology of the digestive organs, were established.
On-and-off deployment technique of a lumen-apposing metal stent during endoscopic pancreatic necrosectomy
Authors: Michihiro Yoshida, Itaru Naitoh, Ruriko Yamada, Kazuki Hayashi, Makoto Natsume, Yasuki Hori, Hiromi Kataoka
Journal: Endoscopy (2019)

Endoscopic ultrasound-guided transmural drainage (EUS-TMD) with lumen-apposing metal stent (LAMS) and endoscopic necrosectomy are widely recognized as effective treatments for walled-off pancreatic necrosis (WON) [1] [2] [3]. However, in particular situations, the LAMS becomes an unexpected encumbrance to endoscopic necrosectomy. Moreover, necrosectomy devices sometimes catch the LAMS incidentally, which might result in LAMS migration.
Abstract 5927: Do Surgically Placed Left Ventricular Leads Provide the Same Benefit as Percutaneous Leads for Cardiac Resynchronization?
Authors: Cory Maxwell, Srijoy Mahapatra, Brian Swenson, Micah Girotti, James Bergin, Irving L Kron, John Kern, Gorav Ailawadi
Journal: Circulation (2008)

Objective : Cardiac resynchronization using a percutaneous left ventricular (LV) lead inserted via the coronary sinus improves symptoms of congestive heart failure (CHF), ejection fraction (EF), and survival. An epicardial LV lead is often placed surgically after failed percutaneous attempt, although it is unknown if they offer the same benefits. The objective of this study was to determine if patients with surgically placed LV leads derive the same therapeutic effect as those with percutaneously placed leads. Methods : Forty-five sequential patients who had surgically placed epicardial LV leads (via thoracotomy or thoracoscopy) after failed percutaneous lead attempt were 3:1 propensity score matched with 135 patients who had successful percutaneous placement. Patients’ scores were matched for the variables age, EF, and QRS interval using greedy methodology. Postoperative outcomes including mortality, CHF readmission, and New York Heart Association (NYHA) class were compared using standard univariate techniques. Results : Mean follow-up was 20±15 months. There were no differences in preoperative variables including age, EF, NYHA class, and etiology of CHF. No differences in 30-day mortality, long-term mortality, CHF readmission rate or EF % increase were identified between groups. Post-procedure complications of acute kidney injury (defined by creatinine increase &gt;1.0: 26.2% vs. 4.9%, P&lt;.001) and infection (11.9% vs. 2.4%, P=.026) were more common in the surgical group. Improvement in NYHA class was more common in the surgical group. Conclusions : Surgical LV lead placement offers functional benefits similar to percutaneous placement and possibly greater likelihood of NHYA class improvement. This comes with the greater risk of reversible acute kidney injury and post procedural infection.
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
Authors: David S. Hong, Nicole Concin, Ignace Vergote, Johann S. de Bono, Brian M. Slomovitz, Yvette Drew, Hendrik-Tobias Arkenau, Jean-Pascal Machiels, James F. Spicer, Robert Jones, Martin D. Forster, Nathalie Cornez, Christine Gennigens, Melissa L. Johnson, Fiona C. Thistlethwaite, Reshma A. Rangwala, Srinivas Ghatta, Kristian Windfeld, Jeffrey R. Harris, Ulrik Niels Lassen, Robert L. Coleman
Journal: Clinical Cancer Research (2019)

Abstract Purpose: Tissue factor (TF) is a potential target in cervical cancer, as it is frequently highly expressed and associated with poor prognosis. Tisotumab vedotin, a first-in-class investigational antibody–drug conjugate targeting TF, has demonstrated encouraging activity in solid tumors. Here we report data from the cervical cancer cohort of innovaTV 201 phase I/II study (NCT02001623). Patients and Methods: Patients with recurrent or metastatic cervical cancer received tisotumab vedotin 2.0 mg/kg every 3 weeks until progressive disease, unacceptable toxicity, or consent withdrawal. The primary objective was safety and tolerability. Secondary objectives included antitumor activity. Results: Of the 55 patients, 51% had received ≥2 prior lines of treatment in the recurrent or metastatic setting; 67% had prior bevacizumab + doublet chemotherapy. Fifty-one percent of patients had squamous cell carcinoma. The most common grade 3/4 treatment-emergent adverse events (AEs) were anemia (11%), fatigue (9%), and vomiting (7%). No grade 5 treatment-related AEs occurred. Investigator-assessed confirmed objective response rate (ORR) was 24% [95% confidence interval (CI): 13%−37%]. Median duration of response (DOR) was 4.2 months (range: 1.0+−9.7); four patients responded for &amp;gt;8 months. The 6-month progression-free survival (PFS) rate was 29% (95% CI: 17%−43%). Independent review outcomes were comparable, with confirmed ORR of 22% (95% CI: 12%−35%), median DOR of 6.0 months (range: 1.0+−9.7), and 6-month PFS rate of 40% (95% CI: 24%−55%). Tissue factor expression was confirmed in most patients; no significant association with response was observed. Conclusions: Tisotumab vedotin demonstrated a manageable safety profile and encouraging antitumor activity in patients with previously treated recurrent or metastatic cervical cancer.
Cytokine Induced Killer (CIK) Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation.
Authors: Ginna G. Laport, Kevin Sheehan, Robert Lowsky, Judith A. Shizuru, Keith Stockerl-Goldstein, Laura J. Johnston, David Miklos, Sally Arai, Jeanette Baker, Robert S. Negrin
Journal: Blood (2006)
Perfect Engraftment after Fludarabine, Cyclophosphamide Plus Thymoglobulin Conditioning Regimen for Unrelated Transplantation in Severe Aplastic Anemia: Phase II Prospective Multi-Center Study in Korea
Authors: Hyoung Jin Kang, Hee Young Shin, Jun Eun Park, Young Tak Lim, Nak Gyun Chung, Bin Cho, Hack Ki Kim, Sun Young Kim, Young Ho Lee, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Ho Joon Im, Jong Jin Seo, Sang Kyu Park, Hyo Seop Ahn
Journal: Blood (2008)
New Frontiers in Irritability Research—From Cradle to Grave and Bench to Bedside
Authors: Neir Eshel, Ellen Leibenluft
Journal: JAMA Psychiatry (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
The Hyperhemolysis Phenotype in Sickle Cell Anemia: Increased Risk of Leg Ulcers, Priapism, Pulmonary Hypertension and Death with Decreased Risk of Vasoocclusive Events.
Authors: James G. Taylor, Vikki G. Nolan, Gregory J. Kato, Mark Gladwin, Martin H. Steinberg
Journal: Blood (2006)
Phase I Dose Escalation Study of Flavopiridol in Combination with Fludarabine and Rituximab: Activity in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma.
Authors: Thomas S. Lin, Beth Fischer, Mollie E. Moran, David M. Lucas, Roshini S. Shank, Eric H. Kraut, Sheriff S. Farag, Margaret S. Lucas, Alexander D. Colevas, Michael R. Grever, John C. Byrd
Journal: Blood (2004)
Single Cell Transcriptomic Analysis of the Multiple Myeloma Bone Marrow Identifies a Unique Inflammatory Stromal Cell Population Associated with TNF Signaling
Authors: Madelon M.E. de Jong, Zoltan Kellermayer, Natalie Papazian, M Duin, Annemiek Broyl, Pieter Sonneveld, Tom Cupedo
Journal: Blood (2019)
Free-Flow Potential Profile along Rat Kidney Proximal Tubule
Journal: Journal of the American Society of Nephrology (2001)

The transepithelial electrical potential difference across rat renal proximal tubule was reinvestigated, using improved techniques. To diminish tip potential artefacts the microelectrodes were filled with HCO 3 - Ringer's solution instead of 3 molar KCI. The error of the potential measurements with HCO 3  Ringer's microelectrodes was tested and was found to be ≤0.5 mV. A significant electrical potential profile was detected along the proximal tubular lumen under free flow. From near zero at the glomerulum the potential difference rose to -1.5 mV, lumen negative, in the first tubular loop at approximately 0.1 to 0.3 mm of tubular length. It decreased then rapidly, changed sign and attained a maximum of ca.2.0 mV, lumen positive, at I mm of tubular length, after which it declined gradually to +1.6 mV in the last accessible loop. The mean of 85 punctures in intermediate and late loops was +1.8, S.D. ±0.33 mV, range +1.0 to +3.2 mV On the basis of perfusion experiments described in the subsequent paper, the lumen-negative potential difference across early loops can be explained as an active transport potential. It is caused by the presence of glucose and amino acids in the glomerular filtrate, which increase the rate of active Na +  absorption over that of active HCO 3  absorption. The lumen-positive potential difference in intermediate and late loops is explained as the sum of a membrane diffusion potential arising from the shift in intratubular Cl -  and HCO 3  concentrations and a small lumen-positive active transport potential from H +  secretion/HCO 3 -absorption.
Abstract 15789: Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies
Authors: Karim Wahbi
Journal: Circulation (2019)

Introduction: An accurate estimation of the risk of life-threatening (LT) ventricular tachyarrhythmia (VTA) in patients with LMNA mutations is crucial to select candidates for implantable cardiover...
Prospective Identification of Resistance Mutants to the JAK2 Inhibitor TG101348.
Authors: John D. Hood, Marcela Alomia, Jon Cao, Chun Chow, Hanna Ehab, Lohse Dan, Mak Chi Ching, McPherson Andy, Noronha Glenn, Tam Betty, Zhu Hong, Richard Soll
Journal: Blood (2007)